Tel Aviv and Boston, MA, December 18, 2025 (Business Wire) -- Syremis Therapeutics debuted with a $165 million Series A financing to develop best-in-class medicines for severe mental health conditions, led by Dexcel Pharma and Third Rock Ventures. The funding will support clinical proof of concept for ST-905, a dual M1/M4 muscarinic agonist already in Phase 1 for schizophrenia, and advance ST-901, a novel NMDA antagonist for major depressive disorder and bipolar depression

Boston, MA, December 18, 2025 (Business Wire) -- PureTech Health plc announced that its Board of Directors has appointed Robert Lyne as Chief Executive Officer (CEO) and a member of the Board, effective immediately. Lyne had served as interim CEO since July 2025 and joined PureTech in January 2024 as Chief Portfolio Officer. His leadership priorities include advancing financing for emerging entities such as Celea Therapeutics following recent regulatory progress, while shar

Paris and Emeryville, CA, December 24, 2025 (Reuters) -- Sanofi announced it will acquire U.S.-based Dynavax Technologies in a deal valued at approximately $2.2 billion, adding an approved adult hepatitis B vaccine and a late-stage shingles candidate to its vaccines pipeline. The transaction, expected to close in Q1 2026, follows recent strategic moves by Sanofi to broaden growth beyond its blockbuster asthma treatment Dupixent, including acquisitions of Vicebio and BluePri

Houston, TX, December 17, 2025 (ACCESS Newswire) -- CNS Pharmaceuticals announced a CEO transition, with industry veteran Rami Levin appointed President and Chief Executive Officer, effective January 1, 2026, following the departure of John Climaco. Levin brings nearly three decades of global leadership experience across oncology, neurology, rare diseases, and cell and gene therapy, including scaling organizations, advancing late-stage programs, and raising capital. The boa

New Brunswick, NJ, December 29, 2025 (PR Newswire) -- Johnson & Johnson has completed its $3.05 billion all-cash acquisition of Halda Therapeutics, adding a differentiated oral oncology platform to its Innovative Medicine portfolio. The deal brings HLD-0915, a once-daily oral prostate cancer therapy designed to overcome resistance mechanisms through Halda’s proprietary RIPTAC™ technology. Beyond prostate cancer, the platform also supports earlier-stage programs across breas

San Francisco, CA, December 15, 2025 (Yahoo Finance) -- OpenAI-backed biotech startup Chai Discovery raised $130 million in a Series B financing round, pushing its valuation to $1.3 billion. The round was led by General Catalyst and Oak HC/FT, with participation from Menlo Ventures, OpenAI, Thrive Capital, SV Angel, Emerson Collective, and others, bringing total funding to more than $225 million. Chai develops AI foundation models for drug discovery, and says its latest pla

Yardley, PA, December 5, 2025 (PR Newswire) -- Jubilant Therapeutics announced the appointment of Daniel J. O’Connor as President and Chief Executive Officer, effective December 1, 2025, as the company advances its clinical-stage oncology and autoimmune pipeline. O’Connor brings more than three decades of leadership experience in biotechnology, most recently guiding Ambrx Biopharma through a period of significant value creation that culminated in its acquisition. His prior

Brisbane, CA, December 09, 2025 (Globe Newswire) -- Vera Therapeutics announced the pricing of an underwritten public offering of just over 6.1 million Class A shares at $42.50 per share, generating approximately $261 million in gross proceeds before fees. The company also granted underwriters a 30-day option to purchase up to an additional 920,716 shares, which could further increase the total raise. Proceeds are expected to support Vera’s late-stage clinical development p

Galway, Ireland, December 17, 2025 (Business Wire) -- AVeta Medical announced the appointment of Karen Noblett, M.D., as Chief Executive Officer, marking a leadership transition as the company advances its VITA AV™ platform for genitourinary syndrome of menopause. Noblett joins from Axonics, where she served as Chief Medical Officer and led clinical strategy, regulatory programs, and physician education supporting the global adoption of sacral neuromodulation technologies.

New York, NY, December 17, 2025 (Reuters) -- Medline shares surged 20.7% in their New York debut after the medical supplies company raised $6.26 billion in an upsized initial public offering, valuing the business at roughly $46 billion and making it the largest U.S. IPO since Rivian’s 2021 listing. Backed by Blackstone, Carlyle and Hellman & Friedman, Medline sold 216 million shares at $29 each, cementing the biggest private-equity-backed IPO on record and the largest globa

Tarrytown, NY and Somerville, MA, December 1, 2025 (Globe Newswire) -- Regeneron Pharmaceuticals and Tessera Therapeutics are collaborating to develop TSRA-196, an in vivo Gene Writing therapy targeting alpha-1 antitrypsin deficiency (AATD), a genetic disease affecting lungs and liver in roughly 200,000 people in the U.S. and Europe. The therapy aims to correct the underlying mutation and restore functional protein through a one-time durable treatment. Tessera will lead ini

Baar, Switzerland and Portsmouth, NH, December 3, 2025 (Business Wire) -- Novocure (NASDAQ: NVCR) named Frank Leonard as its new Chief Executive Officer, effective immediately, following the resignation of Ashley Cordova. Leonard, previously Novocure’s President, has spent over 15 years leading global business operations and helping launch the company’s device-based cancer therapies. William Doyle, Executive Chairman, highlighted Leonard’s pivotal role in shaping Novocure’s

St. Paul, MN, November 20, 2025 (PRNewswire) -- Solventum (NYSE: SOLV) will acquire Acera Surgical, a private bioscience company specializing in fully engineered materials for regenerative wound care, for $725 million in cash plus up to $125 million in milestone-based payments. Acera, founded in 2013, markets Restrata® products in the U.S., used to treat complex, hard-to-heal wounds in acute care settings. Read full article here .

New York, December 3, 2025 (PRNewswire) -- Baird Medical appointed Mark Saxton as CEO of its U.S. subsidiary, bringing over 25 years of medtech leadership including experience at NeuroPace, Smith + Nephew, and Covidien. Saxton will lead U.S. operations, driving the expansion of Baird’s minimally invasive Microwave Ablation (MWA) platform. Read full article here .

Chicago, IL, November 24, 2025 (finance yahoo) -- GE HealthCare (GEHC) announced it will acquire Intelerad, a cloud-based medical imaging software leader, in a $2.3 billion all-cash transaction. The acquisition expands GEHC’s cloud and AI-enabled imaging capabilities across inpatient and outpatient settings, supporting its long-term precision care strategy. The deal brings Intelerad’s outpatient expertise into GEHC’s hospital-focused portfolio, creating a more connected ent

Palo Alto, CA, November 3, 2025 (Business Wire) -- Hippocratic AI raised $126 million in a Series C round, bringing its total funding to $404 million and valuing the company at $3.5 billion. The round was led by Avenir Growth with participation from CapitalG, General Catalyst, Andreessen Horowitz, Kleiner Perkins, Premji Invest, and major health systems including UHS, Cincinnati Children’s, and WellSpan Health. The company plans to use the capital for global expansion, prod

New York, November 12, 2025 (Globe Newswire) -- Ovid Therapeutics unveiled a CEO succession plan in which Meg Alexander will become Chief Executive Officer and join the Board on January 1, 2026, while co-founder Dr. Jeremy Levin shifts to Executive Chairman. The announcement accompanied the company’s third-quarter 2025 financial results and updates on its pipeline progress. Alexander, who has played a key role in shaping the company’s strategy and operations since 2021, wil

New Haven, CT, November 17, 2025 (Reuters) -- Johnson & Johnson will acquire Halda Therapeutics in a $3.05 billion all-cash deal aimed at accelerating Halda’s RIPTAC™ platform for solid tumors. The lead candidate, HLD-0915, recently reported promising Phase 1/2 results in metastatic castration-resistant prostate cancer, showing good tolerability along with reductions in PSA levels and RECIST-based tumor responses. Halda’s broader pipeline includes multiple RIPTAC programs t

Sydney & Boston, November 17, 2025 (Business Wire) -- AdvanCell has appointed biopharma executive Philina Lee, PhD, as its new Chief Executive Officer, effective January 1, 2026. Based in the company’s new U.S. headquarters near Boston/Cambridge, she will spearhead the company’s American expansion while advancing clinical, manufacturing, and partnership efforts for its targeted alpha therapy pipeline. Dr. Lee brings extensive radiopharmaceutical and oncology experience, hav

New York, November 13, 2025 (Business Wire) -- Pfizer completed its purchase of Metsera for $65.60 per share in cash, valuing the company at approximately $7.0 billion, with an additional contingent value right of up to $20.65 per share tied to three clinical and regulatory milestones. The deal adds multiple metabolic assets, including MET-097i, a weekly or monthly GLP-1 RA entering Phase 3, MET-233i, a monthly amylin analog in Phase 1, an oral GLP-1 RA in Phase 1, and addi